MedPath

Effect of Continuous Glucose Monitoring on Course of Glucose in Type 1 Diabetes

Not Applicable
Completed
Conditions
Type 1 Diabetes
Hypoglycemia
Interventions
Device: Real time access to current glucose values during CGMS
Registration Number
NCT00467688
Lead Sponsor
Forschungsinstitut der Diabetes Akademie Mergentheim
Brief Summary

The objective of this cross over study is to access if continuous glucose monitoring (CGMS) with a real time feed back and hypoglycemic as well as hyperglycemic glucose alerts vs. only retrospective analysis of glucose values is able to improve course of glucose with special regard to time spent in hypoglycemic glucose ranges in type 1 diabetic patients with impaired hypoglycemia awareness or a history of severe hypoglycemia. The second objective is to access satisfaction with CGMS during both conditions

Detailed Description

The objective of this cross over study is to access if continuous glucose monitoring (CGMS) with a real time feed back and hypoglycemic as well as hyperglycemic glucose alerts vs. only retrospective analysis of glucose values is able to improve course of glucose with special regard to time spent in hypoglycemic glucose ranges. The second objective is to access satisfaction with CGMS during both conditions.

This study is conducted in an inpatient setting with type 1 diabetic patients. Partisans are asked to have twice a continuous glucose measurement with the GlucoDay System (Menarini Diagnostics). Each measurement period is limited to maximal 48 hours. In one condition the have real time access to current glucose values and alerts are given if glucose is dropping below 70 mg/dl or exceeding 180 mg/dl. During the other condition the participants are blind against their current glucose values and no alerts are given. Glucose course is retrospectively analyzed.

The order of these two conditions is randomized.

Expected outcome:

The primary outcome variable is the daily time spent in hypoglycemic range in type 1 diabetic patients with and without impaired hypoglycemia awareness or a history of severe hypoglycemia. Additionally the patients will also complete questionnaire about satisfaction with CGMS, diabetes related distress, treatment satisfaction, depressive and anxiety symptoms which belongs to the secondary variables.

Inclusion criteria:

* Type 1 diabetes

* Age \> 18 years

* Informed consent

Exclusion criteria:

* Diagnosis and/or treatment of a current psychiatric disease

* Severe late complications

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
50
Inclusion Criteria
  • type 1 diabetes
  • Age > 18 years
  • Informed consent
Exclusion Criteria
  • Diagnosis and/or treatment of a current psychiatric disease
  • Severe late complications

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
A,1Real time access to current glucose values during CGMSReal time access to current measured glucose values; hyperglycemic or hypoglycemic alerts
A,2Real time access to current glucose values during CGMSRetrospective analysis of glucose values
Primary Outcome Measures
NameTimeMethod
Daily time spent in the hypoglycemic glucose range during continuous glucose measurement with and without real time access to glucose values and glucose alarmsduring the 48 hours of using blind vs. unblind continuous glucose monitoring
Secondary Outcome Measures
NameTimeMethod
Time spent in euglycemic and hyperglycemic glucose range Satisfaction with CGMS Diabetes related distress Treatment satisfaction Anxiety and depressive symptomsDuring and after the 48 hours measurement of CGMS

Trial Locations

Locations (2)

FIDAM

🇩🇪

Bad Mergentheim, Germany

Research Institute of the Diabetes Academy Mergentheim

🇩🇪

Bad Mergentheim, Germany

© Copyright 2025. All Rights Reserved by MedPath